Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron Begins Fluvirin Manufacturing After U.K. Clears Site

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K. Medicines & Healthcare products Regulatory Agency lifts its suspension of Chiron's license to manufacture Fluvirin at its Liverpool facility. FDA says it will inspect the facility once "all the critical stages of manufacturing are in full swing."

You may also be interested in...



Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension

The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.

Chiron’s European Flu Vaccine Dose Expectations Cut By 8 Mil.

Only 4 mil. doses of Chiron's Begrivac flu vaccine are expected to be supplied to non-U.S. markets after quality assurance concerns at Chiron’s Marburg, Germany facility leads the company to reduce supply expectations. FDA is beginning to inspect Liverpool plant, where manufacturing problems limited Fluvirin supply for 2004/2005.

Chiron’s European Flu Vaccine Dose Expectations Cut By 8 Mil.

Only 4 mil. doses of Chiron's Begrivac flu vaccine are expected to be supplied to non-U.S. markets after quality assurance concerns at Chiron’s Marburg, Germany facility leads the company to reduce supply expectations. FDA is beginning to inspect Liverpool plant, where manufacturing problems limited Fluvirin supply for 2004/2005.

Related Content

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel